A patent is essentially a government license that gives
certain rights to the patent holder, excluding others from making, using, or
selling a particular product or invention without permission. According to
WIPO’s 2015 World Intellectual Property Indicators Report, there have been more
than 2.7 million patent filings worldwide since 2013 and this number has grown
significantly in recent years. The top three offices in the world have been in
China, the U.S., and Japan. According to the report, the leading technology
fields are computer technology, electrical machinery, measurement, and digital
communication, with medical technology not far behind.
International Stem Cell Corporation (OTCQB: ISCO) is a
publicly traded biotechnology company that promises to advance the field of
regenerative medicine by addressing the problem of immune-rejection. Most
recently, the company has focused its efforts on using unfertilized human eggs
to create parthenogenetic stem cells to treat severe diseases of the eyes and
nervous system, including diseases such as Parkinson’s. The company is careful
to protect its associated intellectual property.
International Stem Cell Corporation protects its technology
worldwide by filing and holding patent applications for its more specific stem
cell lines, methods of production, and various research methods. So far, ISCO
has 16 issued patents and 91 pending patents across 15 patent families, as well
as a licensed portfolio of 25 patents or patents applications across eight
patent families related to its skin care products. Most of International Stem
Cell Corp.’s patents are filed internationally, covering the U.S., Canada, and
a wide range of other industrialized countries.
The company’s technology strengths are backed up by a
carefully chosen team of managers and scientists. ISCO’s directors, executive
managers, and scientific advisors have been selected to benefit the company’s
business and science related operations. Each person is skilled in particular
aspects of corporate management or biotechnology, with executive managers
specializing in systems analysis, strategic planning and corporate management,
as well as financial management, accounting, medical genetics, embryology, and
stem cell biology. This level of combined experience enables ISCO to function
positively in every aspect of its business.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment